Advances in Pancreatic Cancer: Expert Insights to Guide Clinical Practice

Download All
Get up to date on key topics in the contemporary management of patients with resectable and advanced pancreatic cancer with downloadable slides, expert interactive virtual presentations, and an Interactive Decision Support Tool.
Andrew H. Ko, MD
Program Director
person default
Paul E. Oberstein, MD
Program Director
Dan Laheru, MD

ClinicalThought

In this expert commentary, contemporary therapy for patients with resectable and advanced pancreatic cancer are discussed, with a focus on neoadjuvant and adjuvant therapy strategies and targeted therapies for cancers with actionable mutations.

Dan Laheru, MD Released: February 5, 2021

Downloadable Slidesets

Download this concise slideset for expert perspectives on first-line systemic therapy considerations for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director
Released: February 17, 2021

Download this concise slideset for expert perspectives on second-line systemic therapy considerations for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director
Released: February 19, 2021

Download this concise slideset for expert insights into the use of PARP inhibitors as maintenance therapy for patients with advanced pancreatic cancer and specific molecular alterations.

person default Paul E. Oberstein, MD
Program Director
Released: March 5, 2021

Download this concise slideset for expert insights into the current optimal use of neoadjuvant and adjuvant therapy strategies for patients with resectable or borderline resectable pancreatic cancer.

person default Paul E. Oberstein, MD
Program Director
Released: March 1, 2021

Micro Interactive Virtual Presentations

This brief activity provides expert insights into the selection of first-line systemic therapy for patients with advanced pancreatic cancer based on best available evidence.

Andrew H. Ko, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 17, 2021 Expired: February 16, 2022

This short activity provides expert insights into selection of second-line systemic therapy for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 19, 2021 Expired: February 18, 2022

This brief virtual presentation provides expert insights into the use of PARP inhibitors as maintenance therapy for patients with advanced pancreatic cancer and specific molecular alterations.

person default Paul E. Oberstein, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 5, 2021 Expired: March 4, 2022

This brief virtual presentation provides expert insights into the current optimal use of neoadjuvant and adjuvant therapy strategies for patients with resectable or borderline resectable pancreatic cancer.

person default Paul E. Oberstein, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 1, 2021 Expired: February 28, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue